10-Q: Genprex Reports Q1 2025 Results, Focuses on Clinical Trials and Financial Stability

Genprex, Inc. reports its Q1 2025 financial results, highlighting ongoing clinical trials for REQORSA and efforts to secure additional funding amidst going concern uncertainties.

Summary

• Genprex, Inc., a clinical-stage gene therapy company, filed its Form 10-Q for the quarter ended March 31, 2025.
• The company is focused on developing gene-based therapies for cancer and diabetes.
• Genprex's lead oncology drug candidate, REQORSA, is being developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
• The company is currently enrolling patients in Phase 2a expansion of the Acclaim-1 clinical trial (REQORSA and Tagrisso for NSCLC) and Phase 2 expansion of the Acclaim-3 clinical trial (REQORSA and Tecentriq for SCLC).
• Enrollment in the Acclaim-2 trial (REQORSA and Keytruda for NSCLC) has been ceased to prioritize resources.
• Genprex is also developing GPX-002 for Type 1 and Type 2 diabetes, with preclinical studies ongoing at the University of Pittsburgh.
• The company formed a wholly-owned subsidiary, Convergen Biotech, Inc., to focus on the diabetes program.
• Genprex reported a net loss of $3.96 million for the three months ended March 31, 2025, compared to a net loss of $5.97 million for the same period in 2024.
• Research and development expenses decreased to $2.54 million from $3.27 million year-over-year.
• General and administrative expenses decreased to $1.43 million from $2.72 million year-over-year.
• The company's cash and cash equivalents totaled $3.47 million as of March 31, 2025.
• Genprex believes its current cash will be sufficient to fund operations through the end of the second quarter of 2025.
• The company acknowledges the need to raise additional capital to continue funding its development and operations, raising substantial doubt about its ability to continue as a going concern.
• As of May 9, 2025, the company had 27,821,136 shares of common stock outstanding.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive developments in clinical trials and cost reduction, the going concern warning and the need for additional capital raise significant concerns.

Positives

• Net loss decreased by 34% from Q1 2024 to Q1 2025, indicating improved financial management.
• Research and development expenses decreased by 22%, suggesting increased efficiency or strategic prioritization.
• General and administrative expenses decreased by 47%, reflecting successful cost-cutting measures.
• The Acclaim-1 and Acclaim-3 clinical trials are progressing with patient enrollment.
• The FDA has granted Fast Track Designation for the Acclaim-1 and Acclaim-3 treatment combinations, potentially expediting the regulatory review process.
• The Acclaim-3 clinical trial has also received an FDA Orphan Drug Designation, providing potential market exclusivity.
• Formation of Convergen Biotech, Inc. allows for focused development and commercialization of the diabetes program.
• The company has $3.47 million in cash and cash equivalents as of March 31, 2025.

Negatives

• The company has sustained substantial losses from operations since inception and has no current source of revenue.
• Genprex expects to continue to incur significant expenditures to further clinical trials for the commercial development of its patents.
• The company acknowledges the need to raise additional capital to continue funding its development and operations, raising substantial doubt about its ability to continue as a going concern.
• Enrollment in the Acclaim-2 trial has been ceased to prioritize resources, indicating potential challenges with the REQORSA and Keytruda combination.
• The company believes its current cash will be sufficient to fund operations through the end of the second quarter of 2025.

Risks

• The company's ability to raise additional future financing is uncertain.
• Failure to maintain compliance with Nasdaq listing requirements could result in delisting of the company's common stock.
• The company faces competition from larger and/or better-financed biotechnology and pharmaceutical companies.
• The development of marketable products is uncertain, and regulatory approvals may not be obtained.
• The company's intellectual property rights may not be adequately maintained and protected.
• Public health crises could disrupt the company's business, clinical trials, and research programs.
• Delays in regulatory review and approval of product candidates could negatively impact the company's timeline.
• The company is dependent on third-party suppliers or manufacturers to supply or manufacture key ingredients and/or raw materials, products and/or product components and successfully carry out a sustainable, reproducible and scalable manufacturing process in accordance with specifications or applicable regulations.
• There may be no market acceptance for the company's products.
• Changes in third-party reimbursement policies could adversely affect potential future sales of any of the company's products that are approved for marketing.
• The company's disclosure controls and procedures were not effective as of March 31, 2025, due to material weaknesses in internal controls over financial reporting.

Future Outlook

Genprex anticipates needing to raise additional capital to fund future operations, including clinical trials and preclinical work. The company expects to complete interim enrollment of the Phase 2a expansion portion of the Acclaim-1 trial by the end of 2025 and interim enrollment in the Phase 2 dose expansion portion of the Acclaim-3 trial in the second half of 2025. The company believes its current cash will be sufficient to fund operations through the end of the second quarter of 2025.

Management Comments

• Management is actively engaged in remediation efforts to address the material weaknesses identified in the managements evaluation of internal controls and procedures.
• Management evaluated the impact of our failure to maintain effective segregation of duties and sufficient depth of personnel on our assessment of our internal control over financial reporting and has concluded that these control deficiencies represent material weaknesses.

Industry Context

Genprex operates in the competitive gene therapy space, focusing on oncology and diabetes. The company's strategy involves combining its REQORSA therapy with existing approved treatments, which is a common approach in cancer therapy to improve efficacy. The challenges faced in the Acclaim-2 trial, such as enrollment difficulties due to competition, highlight the crowded landscape of clinical trials in NSCLC.

Comparison to Industry Standards

• Genprex's approach of combining REQORSA with established therapies like Tagrisso (osimertinib) and Tecentriq (atezolizumab) mirrors strategies employed by companies like Amgen with Lumakras and Mirati Therapeutics with Adagrasib, which are KRAS G12C inhibitors used in combination therapies for NSCLC.
• The company's focus on gene therapy for diabetes, similar to Vertex Pharmaceuticals' efforts with stem cell-derived islet cells, represents a novel approach to addressing unmet medical needs in this area.
• The reported net loss of $3.96 million for Q1 2025 is within the range of losses reported by other clinical-stage biotech companies of similar size, such as Mustang Bio and Celularity, which are also heavily investing in research and development.
• The cash runway extending through the second quarter of 2025 is a critical factor, as many biotech companies aim for at least 12 months of cash on hand to ensure operational continuity and attract investment.

Related Party Transactions

• In April 2009, prior to Mr. Varner becoming an officer and director of Genprex in August 2012, the Company entered into an Assignment and Collaboration Agreement with IRI, providing Genprex with the exclusive right to commercialize a portfolio of intellectual property.

Stakeholder Impact

• Shareholders face uncertainty due to the company's need for additional funding and the going concern warning.
• Employees may be affected by potential cost-cutting measures or changes in strategic direction.
• Patients could benefit from successful development and approval of the company's therapies.
• Suppliers and creditors face increased risk due to the company's financial instability.

Next Steps

• Complete enrollment of the first 19 patients for interim analysis in the Phase 2a expansion portion of the Acclaim-1 study by the end of 2025.
• Conduct interim analysis in the first half of 2026 for the Acclaim-1 study.
• Complete enrollment of the first 25 patients for interim analysis in the Phase 2 expansion portion of the Acclaim-3 study in the second half of 2025.
• Seek further regulatory guidance from the FDA on IND-enabling studies for the diabetes program in the second half of 2025.
• Continue working with the University of Pittsburgh on species analyses for the animal models as well as on other regulatory and clinical strategic planning, including the planned initiation of research in Type 2 diabetes animal models.
• Assess potential actions to regain compliance with the Nasdaq Minimum Bid Price Requirement and may, if appropriate, consider and effectuate available options, including implementation of a reverse stock split of our common stock.
• Continue remediation efforts to address the material weaknesses identified in the managements evaluation of internal controls and procedures.

Key Dates

Keywords

Genprex, REQORSA, Gene Therapy, Clinical Trials, NSCLC, SCLC, Diabetes, GPX-002, ONCOPREX, Tagrisso, Tecentriq, Financial Results, Going Concern, Capital Raise, Acclaim-1, Acclaim-3, Convergen Biotech